Prostate cancer (PCa) has been largely known as an androgen-dependent malignancy since 1942, when Hodges and Huggins first recognized the strong connection between androgens and PCa progression [1], and it is now well established that its pathogenesis and progression are mediated by the androgen receptor (AR) [2]. This evidence concerns the gene AR and prostate carcinoma.